Traditional biologics manufacturing, reliant on sequential batch processing operations, faces significant limitations such as low productivity, lengthy processing times, and frequent manual interventions. High operational costs due to the infrastructure needs of batch processes account for a large portion of fixed costs for producing biologics like monoclonal antibodies (mAbs). For modern manufacturers, Enzene’s commercially validated, fully-connected continuous manufacturing™ (FCCM™) technology reduces costs and has a smaller facility footprint, making it possible to produce quality medicines at more affordable costs.
In this GEN webinar, Veerendra Kumar Reddy, PhD, will introduce Enzene’s FCCM technology and discuss how it enables affordable and accessible protein therapeutics manufacturing. The EnzeneX™ platform operates continuously from upstream to downstream with a smaller facility footprint, enabling up to 10x greater productivity than traditional batch processing due to higher cell densities. The most recent version of the platform is projected to reduce mAb production costs to less than $40 per gram, making life-saving medicines more affordable and accessible globally.
Key takeaways from the webinar include:
Discover how EnzeneX leverages alternating tangential flow (ATF) perfusion and automated multi-column chromatography to enable continuous biologics production
Explore how FCCM processes reduce production costs and achieve up to 10x higher productivity compared to fed-batch manufacturing
Learn how EnzeneX reduces the facility’s equipment and carbon footprint for more sustainable biologics manufacturing
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
